Výsledky vyhledávání - "Anemia, Refractory/therapy"

Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes

Autor: Tsiara, S. N., ELENI KAPSALI, Panteli, K., Christou, L., Bourantas, K. L.

Publikováno v: Scopus-Elsevier

Amifostine is a cytoprotective agent mainly used in cancer therapies, in order to ameliorate the toxic effects of anticancer chemotherapy and radiotherapy. In the past years an intriguing number of applications of amifostine have been identified; one

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::dfe2b38b03a55c9ac99ce9c78f788211
http://olympias.lib.uoi.gr/jspui/handle/123456789/19136

Zobrazit plný text záznamu

Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone

Autor: Tsiara, S. N., Chaidos, A., Gouva, M., Christou, L., Panteli, K., ELENI KAPSALI, Bourantas, K. L.

Publikováno v: Europe PubMed Central
Scopus-Elsevier

Myelodysplastic syndromes (MDS) are a heterogenous group of hematological clonal malignancies. Patients belonging to the refractory anemia (RA) subtype are usually treated with recombinant human erythropoietin (EPO). Not all patients respond to EPO a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5c5e58b8bcead6fb1f1383259d2ca991
http://europepmc.org/abstract/med/15149150

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání